I'm the person who keeps our clinical procurement checklist. For the last seven years, I've handled device orders for a cardiology clinic, and I've made enough mistakes to fill a pretty embarrassing binder. The worst ones all share one cause: I compared the wrong things.

Back in 2021, I said “we need fast lab results.” The vendor of a chemistry analyzer heard “we need stat capability.” We bought the machine, installed it, and quickly learned that our pacemaker clinic was the opposite of a stat lab. We needed predictable, batched results before the next patient's appointment—not a single urgent result that interrupted everything. That was a $6,800 misunderstanding (plus a week of staring at a machine we were afraid to use).

That's why I now build comparison charts before buying anything. If you've ever used a Fujifilm camera comparison chart, you know the rule: more megapixels doesn't automatically mean a better camera. The Fujifilm X Half digital camera—or any compact with a weird retro name—might be perfect for one shooter and useless for another. Same logic applies to diagnostic equipment. So for the last three months, I've been comparing two categories that look similar but aren't: point-of-care pulse oximetry and a centralized chemistry analyzer. Here's what I'd tell my 2021 self.

The comparison framework: two tools, two jobs

For a pacemaker clinic, the decision isn't usually “pulse oximeter or chemistry analyzer?” It's “does our current pulse oximeter give us enough information?” Medicare and many private insurers now expect documented oxygen saturation during device checks, but that's a vital sign, not a lab panel. A patient can have normal SpO2 and a potassium level of 6.8. No pulse oximeter on the market catches that.

The comparison should happen on four dimensions:

  • What the test actually measures
  • Time from sample to decision
  • Total cost per clinically useful result
  • Training and trust for staff

We'll compare a handheld pulse oximeter (the kind in every exam room) with a Fujifilm DRI-CHEM chemistry analyzer—two very different answers to “is this patient okay?”

Dimension 1: What it measures

A pulse oximeter is elegant. How does a pulse oximeter work? It shines two wavelengths of light—red around 660 nm, infrared around 940 nm—through a fingertip. Oxygenated hemoglobin absorbs more infrared light; deoxygenated hemoglobin absorbs more red. The device measures the pulsatile change in absorption and calculates SpO2. It's fast, noninvasive, and genuinely useful for respiratory status.

The problem is scope. A pulse oximeter tells me how well oxygen is moving from the lungs to the blood. It says nothing about creatinine, hemoglobin A1c, electrolytes, or liver enzymes—all of which matter when you're managing a pacemaker patient on anticoagulants. A Fujifilm DRI-CHEM analyzer uses dry slides to measure multiple analytes from a few drops of serum. It answers the question my cardiologists actually ask: “Can we safely continue this medication?” or “Is this patient stable enough for reprogramming?”

Conclusion: The pulse oximeter is a warning light; the chemistry analyzer is a dashboard. You don't skip the warning light, but you can't run a clinic on it.

Dimension 2: Time from sample to decision

If you compare by speed alone, the pulse oximeter wins instantly. It provides continuous readings with zero sample prep. The chemistry analyzer needs a blood draw, a centrifugation step, a slide, maybe several minutes for the dry chemistry reaction, and a result that someone has to verify against controls.

But “faster” isn't the same as “more certain.” In our clinic, the real bottleneck was not the analyzer's cycle time—it was the workflow around it. We got a stat-capable device in January 2022. The machine itself was fast. But we only ran samples in two batches per day because the operator had other duties. So the “8-minute result” became a “6-hour result” when the sample sat on a bench waiting for the batch. Meanwhile, a nurse with a pulse oximeter could get an SpO2 in seconds, but that number didn't move the clinical plan.

Here's the counterintuitive part: the slower technology gave us more trustworthy decisions. The pulse oximeter was immediate but incomplete; the chemistry analyzer was delayed but definitive. For a pacemaker patient, I'll take a definite result in 20 minutes over a no-result in 2 seconds.

Conclusion: Measure decision turnaround, not device speed. Speed is worthless if you have to verify or redo it.

Dimension 3: Total cost per usable result

I once showed our CFO a comparison chart that made a pulse oximeter look like the obvious choice. Low upfront cost, no consumables, no calibration, no training. It looked unbeatable. Then an audit showed we were sending out an average of 14 chemistry panels per week to a reference lab, paying $42 per panel in courier and processing fees. That was $28,392 per year for results that came back two days later. When a pacemaker patient needs a medication adjustment, two days is not a result; it's a delay with a bill attached.

People think a chemistry analyzer is expensive because it's complex. Put another way: the analyzer is costly up front, but the pulse oximeter strategy was costly per decision. The surprise wasn't the analyzer's price. It was how much hidden value came with the alternative—reagent cost per test, same-visit results, and no courier chase. For our volume, the Fujifilm DRI-CHEM systems paid for themselves in about nine months.

I'm not saying you should buy an analyzer for every clinic. But I am saying that “cheap per reading” is the wrong denominator. The right denominator is “cost per result that changes a care decision.” A pulse oximeter might give you 100 readings a day, but if one patient's abnormal potassium is missed, that's a $15,000 readmission—or worse.

Conclusion: The lower price per test loses to the lower cost per correct action.

Dimension 4: Training and trust

Any medical assistant can place a pulse oximeter on a finger. Fewer people understand why a low SpO2 reading can be wrong (cold extremities, nail polish, irregular pulse—hello pacemaker patients). The pulse oximeter gives the illusion of simplicity.

The chemistry analyzer is scarier at first. But Fujifilm's operator training program—and their dry-slide design—makes the actual daily routine easier than I expected. As of January 2025, Fujifilm's DRI-CHEM product materials still emphasize reduced liquid-handling steps as a key feature. The dry slides remove many handling errors. Still, you have to document controls and maintenance. That's not a bug; it's the point. Trust comes from a demonstrated QC history, not from a brand logo.

We bought the analyzer because the vendor's training package included on-site competency checks and a 24-hour support line. I don't need a device to be “smart.” I need my staff to be sure they can operate it without a 3am panic call. There is something satisfying about seeing a clean QC report at the end of the week. After the chaos of sending labs out and chasing phone calls, that quiet consistency is the payoff.

What I'd recommend for a pacemaker clinic

Buy the pulse oximeter. It's a mandatory tool for screening. But if you're managing anticoagulation, renal function, or electrolyte stability in pacemaker patients, add a chemistry analyzer to the room. The pulse oximeter tells you if the patient is alive; the chemistry analyzer tells you what to change next.

And yes, the same reasoning applies to the camera world. A Fujifilm camera comparison chart doesn't rank the Fujifilm X Half digital camera above everything else—it places it in a context. If you're a street photographer who wants a small discreet body, the X Half might be perfect. If you're shooting sports, you need a different system. The “best” diagnostic tool works the same way. It depends on the workflow, the patient population, and the cost of being wrong.

In February 2024, we paid $180 for expedited reagent delivery because I reordered late. I hated that fee. But the alternative was rescheduling 11 pacemaker visits, which would have cost more in lost confidence and delay. The fee bought certainty. After my previous mistakes, I now treat certainty as part of the purchase price.